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Abstract Regeneration of myelin sheaths (remyelination)
after central nervous system demyelination is important to
restore saltatory conduction and to prevent axonal loss. In
multiple sclerosis, the insufficiency of remyelination leads to
the irreversible degeneration of axons and correlated clinical
decline. Therefore, a regenerative strategy to encourage
remyelination may protect axons and improve symptoms in
multiple sclerosis. We highlight recent studies on factors that
influence endogenous remyelination and potential promising
pharmacological targets that may be considered for enhancing
central nervous system remyelination.
Keywords Multiple sclerosis . Remyelination . Stem cell .
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Introduction: The Need for Regenerative Therapy
in Multiple Sclerosis
Multiple sclerosis (MS) is a disease of the central nervous
system (CNS) characterized by acute focal demyelination,
variable remyelination, and extensive neuronal and axonal
degeneration [1]. MS affects approximately 2.5 million
people worldwide and is thought to be the most commonly
acquired neurological disease of young adults.
There are 2 principal components in treating MS: 1) the
prevention of damage, usually involving an immunomod-
ulatory approach; and 2) the repair of damage, involving
the regeneration of new myelin sheaths (remyelination) [2,
3]. Protection of neurons and their axons, the loss of which
is the principal anatomical correlate of progressive clinical
deterioration, might be considered a third component [4].
Indeed, the overarching goal of all MS therapy is to identify
strategies to prevent axonal loss. Axon protection can be
achieved directly as a result of intervention in the
mechanisms by which axons are injured or degenerate [5].
However, axon protection can also be achieved as a
consequence of immunomodulatory therapies and by the
promotion of remyelination.
MS research for many decades has resulted in a
considerable investment into the immunological aspects of
the disease, as reflected in the identification of several
immune-related genes as genetic determinants of disease
susceptibility [6] and an understanding of the disease
pathogenesis [1, 7]. Although this research has proven to
be highly informative and has translated into the develop-
ment of highly effective immunomodulatory therapies, our
knowledge pertaining to aspects of the disease is not
directly related to immunology, but it is related to
neurobiology instead, and specifically the interdependency
between axon and oligodendrocytes remain relatively to be
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less explored [8, 9]. Thus, although immunomodulatory
therapies are proving to be increasingly effective in
controlling the initial relapsing-remitting phase of MS, the
secondary progressive phase, in which there is continual
atrophy of demyelinated axons, remains largely untreatable.
Indeed, axon degeneration occurs despite immunomodula-
tory therapies, suggesting that axon integrity and protection
may occur through mechanisms independent of inflamma-
tion [10, 11]. Several lines of evidence suggest that the
basis of axon atrophy in chronically demyelinated lesions is
due, in part, to the absence of myelin-associated trophic
signals that are critical for maintaining axon integrity. For
example, oligodendrocyte-specific deletions in myelin
associated genes PLP, MAG, and CNPase do not cause
any obvious defect in myelination, but eventually lead to
axonal pathology [12–14]. Moreover, axon degeneration
has recently been observed as a consequence of genetically-
induced oligodendrocyte-specific ablation [15], thus pro-
viding compelling evidence that axon survival is dependent
on intact oligodendrocytes, and that axon degeneration in
chronically demyelinated lesions can occur independently
of inflammation. The presence of low-grade inflammation
(mainly cells of the innate immune response) has led to the
suggestion that this inflammatory response may also
contribute to progressive attritional axonal loss. However,
it is far from clear whether this inflammation is a primary
cause of axonal degeneration or a secondary response to
axonal degeneration occurring due to loss of myelin-
associated trophic support. Importantly, the increasing
evidence of a role for myelin in preserving axon integrity
reveals an evermore pressing need to understand the
mechanisms of CNS remyelination.
In addition to preserving axon integrity [16, 17],
remyelination also restores saltatory conduction and
reverses functional deficits [18–20]. Compelling evidence
in support of functional restoration by remyelination has
recently been provided by an unusual demyelinating
condition in cats in which the reversal of clinical signs is
associated with spontaneous remyelination [21]. Taken
together these observations imply that an effective means
of restoring function and preventing axonal loss in MS is to
promote remyelination.
Remyelination as Regenerative Therapy
How might remyelination in MS be enhanced? One
proposed approach is to transplant myelinogenic cells of
which several types have been described. However, this
approach presents a variety of obstacles, including how to
achieve: 1) the proper delivery and distribution of cells
within a multifocal disease, 2) efficient remyelination by
exogenous cells in environments that do not support
remyelination by endogenous cells, and 3) a generation of
a large numbers of cells that may require immunosuppres-
sive protocols. For these and other reasons, cell transplan-
tation with the primary objective of remyelination is a
regenerative strategy for MS fraught with translational
difficulties. An alternative approach is to identify ways to
enhance remyelination by endogenous myelinating cells.
Such an approach requires an understanding of precisely
how remyelination is achieved and why it fails.
The principal source of new remyelinating cells is an
abundant and widely distributed population of cells in the
adult CNS traditionally called oligodendrocyte precursor
cells (OPCs). In the adult CNS, these cells are both self-
renewing and multipotent, having been observed to give
rise to certain neurons, astrocytes (albeit rarely), and
Schwann cells, as well as oligodendrocytes in vivo, and so
can reasonably be regarded as a type of adult neural stem
cell [22–25]. The response to demyelination causes OPCs
to become activated, a morphological change accompanied
by upregulation of genes not normally expressed in the
resting state [26–29]. Activated OPCs proliferate, migrate
and rapidly fill up the demyelinated lesions at a density that
far exceeds that in normal tissue. To complete the
remyelination process, the cells exit the cell cycle and
differentiate into myelin sheath-forming oligodendrocytes,
which is a complex process involving axon engagement,
ensheathment and formation of compacted myelin [30, 31].
As with all regenerative processes the efficiency of
remyelination decreases with age primarily due to a
decrease in the ability of recruited cells to differentiate
[32–35]. This age-associated decline in remyelination
resembles and may be in part a determinant of a now
well-recognized feature of many chronically demyelinated
MS lesions, which are replete with oligodendrocyte lineage
cells that are unable to differentiate into myelinating
oligodendrocytes [36–39].
Thus, both experimental and clinical pathological studies
point to the impairment of precursor differentiation as a
common, although not exclusive, feature of insufficient or
failed remyelination in MS. This means that identifying
pathways involved in the regulation of OPC differentiation
represents a critical task in understanding the mechanisms
of remyelination and the development of new pharmaco-
logical therapies for enhancing endogenous remyelination,
and thus axonal protection in MS.
Barriers Preventing Efficient Remyelination
Myelin Debris
The process of primary demyelination creates vast amounts
of myelin debris from the unraveling and breakdown of
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compacted myelin from axons. Myelin fragments in lesions
can prevent efficient remyelination by inhibiting oligoden-
drocyte differentiation. Several lines of evidence reveal that
the phagocytic removal of myelin debris is critical for
efficient remyelination. First, rapid remyelination that
occurs in young animals is associated with efficient
removal of myelin debris in contrast to old animals that
display slow remyelination and impaired clearance of
myelin debris [40, 41]. It is thought that inefficient debris
clearance is due to delayed activation and recruitment of
phagocytic macrophages. Second, in tissue culture, OPCs
plated onto a CNS myelin substrate display significantly
impaired differentiation, although their migratory and
proliferative properties are unaltered [42]. Third, injection
of myelin debris into experimentally induced areas of
demyelination in young animals results in impaired
remyelination caused by the inhibition of precursor differ-
entiation [43]. Recently, the Fyn-Rho-ROCK and protein
kinase C (PKC) signaling pathways has been identified as
critical mediators of myelin-associated inhibition [44].
Hyaluronan
The glycosaminoglycan hyaluronan is another component
found to inhibit OPC differentiation and remyelination [45].
Hyaluronan has been observed to accumulate in chronic
MS lesions and in mice with experimental autoimmune
encephalomyelitis (EAE). High molecular weight hyalur-
onan can directly inhibit OPC differentiation in culture. A
recent study has found that hyaluronan inhibits OPC
differentiation by binding to toll-like receptor 2 (TLR2) in
oligodendrocyte lineage cells in culture and that hyalur-
onidases produced by OPCs convert high molecular weight
hyaluronan to the more inhibitory low molecular weight
form [46]. Moreover, inhibition of TLR2 and its signaling
pathways can block hyaluronan inhibition to enable OPC
differentiation. In MS lesions, TLR2 is upregulated and
expressed by oligodendrocytes, thus suggesting that
hyaluronan-mediated inhibition of OPC differentiation
may occur through TLR2 signaling.
Semaphorins
Semaphorins have been implicated as key regulators of
several stages of remyelination. Both experimental func-
tional studies and expression analysis of MS lesions support
a model in which recruitment is regulated by an appropriate
balance of semaphorin 3A, a repulsive guidance cue, which
if it becomes the dominant form may prevent precursors
entering areas of demyelination, and semaphorin 3F, an
attractive guidance cue that facilitates recruitment [47, 48].
Semaphorin 3A has also been shown to be a potent
inhibitor of precursor differentiation (a role which paradox-
ically might be advantageous to recruitment by preventing
cells leaving the cell cycle) and therefore a potential
therapeutic target for overcoming remyelination block in
nonremyelinating MS lesions [49].
Although the concept of these or indeed other inhibitors
of differentiation, such as poly-sialated neural cell adhesion
molecule (PSA-NCAM) [50], as causes of remyelination
failure are derived mainly from experimental studies and
inferred from descriptive observations of MS tissues.
Nevertheless, these studies raise important questions as to
the existence of signaling pathways in OPCs that respond to
extrinsic inhibitory factors, thus offering possible therapeu-
tic targets to overcome remyelination block in the hostile
environment of MS lesions.
Pharmacological Targets of Remyelination
Several regulators of CNS remyelination have been recently
identified that potentially lend themselves to pharmacological
manipulation, including LINGO-1, Notch1, Wnt, and retinoid
X receptors (RXRs). These signaling pathways are particularly
interesting because pharmacological agonists or antagonists
against are available (or are currently being developed) for
treatment against other diseases, such as cancer. LINGO-1,
Notch, and Wnt signaling in OPCs are negative regulators of
OPC differentiation, whereas RXRs are positive regulators of
differentiation. By targeting these pathways, it might be
possible to pharmacologically encourage remyelination from
endogenous OPCs as a regenerative strategy to treat MS
(Fig. 1).
LINGO-1
LINGO-1 was identified in a search for CNS-specific
leucine rich repeat proteins [51]. It has been shown to
regulate axon outgrowth by interaction with the Nogo-66
receptor complex. More recently LINGO-1 has also been
found to be a negative regulator of oligodendrocyte
differentiation [52]. Treatment of cultured OPCs with small
interference RNAs (siRNAs) generated against LINGO-1,
dominant negative LINGO-1, or soluble LINGO (LINGO-
Fc) resulted in increased morphological differentiation of
oligodendrocytes as characterized by the abundance of
terminal membrane sheets. Mice deficient in LINGO-1 or
treated with an antibody antagonist against LINGO-1
exhibited increased remyelination and functional recovery
from EAE, a model of immune-mediated demyelination
[53]. Moreover, the LINGO-1 antagonist is able to promote
CNS remyelination by directly stimulating OPC differenti-
ation in nonimmune, toxin-induced models of demyelin-
ation in rats [54]. These findings reveal the importance of
LINGO-1 signaling in regulating OPC differentiation in the
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injured CNS. Moreover, the restricted expression of
LINGO-1 in the CNS makes therapeutic targeting of
LINGO-1 potentially advantageous for improving myelin
repair without affecting non-neural tissues.
Wnt Signaling
A screen for transcription factors associated with CNS
remyelination in experimentally demyelinated mice led to
the identification of Tcf4 expression in oligodendrocyte
lineage cells and the elucidation of the canonical Wnt
pathway as a negative regulator of precursor differentiation
[55]. Tcf4 is expressed in the mouse white matter
immediately after birth, but it is barely detectable in the
adult [55–57]. However, following CNS injury, Tcf4 is re-
expressed and upregulated in OPCs that are recruited to the
lesion [56]. Moreover, Tcf4 is highly expressed in active
MS lesions, suggesting a role in remyelination. In response
to Wnt activation, Tcf4 is thought to interact with β-catenin
in the nucleus to regulate transcription of Wnt-β-catenin
pathway target genes [58]. Indeed, disruption of Wnt
signaling in oligodendrocyte lineage cells by using trans-
genic mice that actively express a dominant active β-
catenin gene results in mice displaying severe tremor and
ataxia within 1 week after birth due to delayed oligoden-
drocyte differentiation and hypomyelination [55]. However,
this effect is transient as CNS myelination ultimately
catches up and appears normal in adult mice. Experimental
demyelination performed on these transgenic mice results
in a similar delay in oligodendrocyte differentiation and
remyelination, without affecting OPC recruitment to
lesions. These findings have opened up a new area of
research to dissect the mechanism of Wnt signaling in OPC
differentiation. But more importantly, given the growing
interest to develop pharmacological inhibitors against the
Wnt pathway in cancer therapy [59], it might be possible in
the near future to use Wnt inhibitors to stimulate OPC
differentiation and improve CNS remyelination in MS.
Fig. 1 Pharmacological targets of central nervous system (CNS)
remyelination. The diagram illustrates the recruitment of an oligoden-
drocyte precursor cell (OPC) to an area of demyelination, and its
differentiation into a remyelinating oligodendrocyte. Chronically
demyelinated axons that do not acquire remyelinated sheaths are
liable to undergo degeneration. Conversely, stimulation of remyelination
preserves the integrity of axons. Several molecular pathways known to
regulate oligodendrocyte differentiation are possible pharmaceutical
targets of CNS remyelination. Semaphorin 3A and 3F are involved in
OPC recruitment into the lesion. Lingo-1, Wnt/β-catenin, Semaphorin
3A, and canonical Notch signalling pathways negatively regulate CNS
remyelination by preventing OPC differentiation, whereas retinoid X
receptor (RXR)-γ and the noncanonical Notch signalling pathways
enhance CNS remyelination by stimulating OPC differentiation
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Notch Signaling
One of the potential contributors of remyelination efficiency in
MS is thought to be reactive astrocytosis in lesions, which can
potentially have both beneficial and detrimental roles [60, 61].
In search of putative astrocytic inhibitors of remyelination, a
microarray analysis was performed on purified human
astrocytes treated with cytokines that are known to be
significantly upregulated in the brains of MS patients [62].
This led to the identification of the Notch ligand, Jagged in
astrocytes, which is upregulated in response to the cytokine
TGF-β. Notch1 and its effector Hes5 were detected in
immature oligodendrocytes of MS lesions and following
demyelination in mice [62, 63]. When cultured human OPCs
were exposed to Jagged, these OPCs failed to mature [62].
However, the role of Notch1 signaling on OPC differentiation
during remyelination in vivo has remained inconclusive for
several reasons. First, remyelination can occur with great
efficiency despite the expression of Notch in precursor cells
and Jagged expression within the demyelinated environment
[63, 64]. Second, conditional ablation of Notch in precursors
leads to no [63] or a relatively minor effect on remyelination
efficiency [65]. Third, when mice with experimental autoim-
mune encephalomyelitis (a model of immune mediated
demyelination) were treated with a γ-secretase inhibitor,
MW167, which prevents Notch signaling, myelin repair and
axonal survival were improved [66]. However, Notch is also
expressed by cells associated with inflammation [67], thus it
remains possible, even likely that the mechanism by which
MW167 enhances CNS myelin repair occurs through
immunomodulation rather than by directly stimulating OPC
differentiation. It would be of interest to assess the effect of
MW167 directly on OPC differentiation and myelination by
using purified OPC cultures or myelinating co-cultures.
Fourth, noncanonical Notch signaling in OPCs is involved
in the induction of OPC differentiation [68]. Indeed, evidence
from careful examination of MS tissue implies a failure of
Notch signaling as an explanation for incomplete differenti-
ation [69]. Within OPCs present in nonrepairing lesions, the
Notch intracellular domain accumulates outside the nucleus
and therefore cannot activate the expression of downstream
targets. The perinuclear aggregation of the Notch intracellular
domain is attributed to an increased expression of TAT-
interacting protein 30 kDa (TIP30), which leads to an
inhibition of the nuclear transporter importin-β. Thus, the
value of Notch signaling as a therapeutic target for
remyelination remains uncertain
Retinoid X Receptors (RXRs)
Thus far, most studies have focused on the negative
regulation of OPC differentiation in remyelination. Recently,
RXRs have been demonstrated as positive regulators of OPC
differentiation. RXRs are nuclear receptors that regulate cell
proliferation and differentiation [70, 71]. There are 3
members in the RXR family (RXRα, RXRβ, and RXRγ)
that form homodimers or heterodimers with other nuclear
receptors, including retinoic acid receptors (RAR), thyroid
hormone receptors, vitamin D receptors (VDR), peroxisome
proliferator activator proteins (PPAR), and liver X receptors
(LXR), to control transcription of target genes. Following
CNS injury, all 3 members of RXR are highly expressed in
lesions [72]. We have recently found that RXRγ is highly
expressed in oligodendrocyte lineage cells during the
regenerative phase of CNS remyelination by using micro-
array analysis of the separate stages of CNS remyelination in
rats. In acute and remyelinating MS lesions, RXRγ is highly
expressed by oligodendrocyte lineage cells, macrophages, and
astrocytes, but its expression is very low in chronic inactive
lesions, suggesting RXRγ is an active component of CNS
repair. Transfection of cultured OPCs with small interference
RNAs generated against RXRγ resulted in less morpholog-
ically differentiated oligodendrocytes. Analysis of RXRγ
knockout mice that have received focal CNS demyelination
resulted in the accumulation of undifferentiated OPCs and less
mature oligodendrocytes in lesions. These results indicate
RXRγ regulates oligodendrocyte differentiation.
The mechanisms of RXR signaling and its regulation
during CNS remyelination are presently unclear. As with
other nuclear receptors, RXRs are ligand-induced transcrip-
tion factors that function through heterodimeric association
with other nuclear receptors. However, RXR is seated at the
center of nuclear receptor activity, because it can hetero-
dimerize with a wide range of receptors, including members
of RAR, thyroid hormone receptor, PPAR, LXR, and VDR.
Once activated, the RXR heterodimeric complex is able to
induce transcription of genes associated with cell differen-
tiation. Moreover, RXRs are able to function as either
permissive or nonpermissive heterodimers. In permissive
dimerization, such as RXR:PPAR or RXR:LXR, the
complex can be activated by RXR selective ligands, such
as 9cRA, whereas in nonpermissive dimerization, such as
RXR:RAR, RXR:thyroid hormone receptors or RXR:VDR,
the complex can only be activated by ligands selective for
the partners of RXR, and not by RXR selective ligands
alone, so that RXR activity is subordinated under nonper-
missive dimerization. Because we found that RXR activa-
tion enhances CNS remyelination, the mechanism by which
RXR signaling occurs in oligodendrocytes is likely through
permissive heterodimerization, such binding to PPAR or
LXR. Interestingly, PPARγ, which is also expressed by
oligodendrocyte lineage cells, has been shown to accelerate
oligodendrocyte differentiation when it is activated [73].
Moreover, deletion of LXRγ and LXRβ in mice results in
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dysmyelination or myelin abnormalities [74]. Identification
of the RXR heterodimeric partner would therefore improve
our understanding of RXR signaling in oligodendrocyte
lineage cells, and help develop more finely tuned agonists
that would target oligodendrocytes specifically in remyeli-
nation therapy.
Chemical agonists and antagonists of RXR signaling, or
rexinoids, are widely available and are showing promise in
the treatment of certain types of cancers and metabolic
disorders [75]. When cultured OPCs are exposed to the
RXR selective antagonists (HX531 and PA452), oligoden-
drocyte differentiation is severely impaired. By contrast,
when OPCs are exposed to the RXR agonists, 9-cis-retinoic
acid (9cRA), HX630, or PA024, oligodendrocytes are
stimulated to differentiate and form myelin membrane-
like sheets in culture. Further experiments testing the
effect of 9cRA on ex vivo cerebellar slice cultures of
demyelination, as well as on rats that have received focal
demyelination in the CNS, resulted in the significant
increase of remyelinated axons. Moreover, axons in
lesions displayed thicker myelin sheaths in 9cRA treated
rats compared to controls at an early stage of remyelina-
tion, suggesting 9cRA accelerated CNS remyelination. It
is known that RXR agonists can also attenuate inflamma-
tion by regulating macrophage activity [76]. Immunomo-
dulation and acceleration of OPC differentiation are the
crucial ingredients needed for successful MS treatment.
Rexinoids may exert dual functions in regulating inflam-
mation and OPC differentiation in the injured CNS, thus
showing promise as feasible regenerative therapeutics to
improve CNS remyelination in demyelinating diseases
such as MS.
Conclusions and Future Prospects
It is now widely acknowledged that inducing differentiation
of oligodendrocyte lineage cells present within areas of
demyelination into remyelinating oligodendrocytes repre-
sents a major focus of therapeutic remyelination research.
Potentially this could be achieved either by overcoming
putative inhibitors of differentiation present within lesions
or by the administration of agents that induce differentia-
tion. Critical to achieving this objective is the identification
of pathways by which oligodendrocyte differentiation is
controlled. In this review, we have identified several
pathways associated with preventing differentiation for
which the formulation of effective antagonists would be
expected to have therapeutic efficacy. However, much work
is yet to be done to achieve a comprehensive understanding
of molecular logic underlying optimal remyelination. In this
regard, genomic [77], gene expression [78] and proteomic
[79] analyses of MS patients will be critical.
Developments in the pharmacology of “patient-tailored”
cancer treatment may provide such regenerative medicines in
a shorter time frame than might have been predicted several
years ago. Differentiation therapies have been attracting
considerable interest in cancer medicine and are predicated
on the hypothesis that inducing a cancer cell to differentiate
will either convert it into a nondividing cell or, more likely,
cause it to undergo apoptosis [80]. The objectives of cancer
differentiation therapies in promoting cell differentiation are
thus strikingly similar to those of regenerative medicine and
especially the enhancement of remyelination. One can
therefore envisage a situation in which drugs developed for
cancer therapy can be re-designated for remyelination
therapy. As a specific example, several cancers, including
the majority of colon adenocarcinomas, arise due to gain-of-
function mutations in the canonical Wnt signaling pathway.
Pharmacological inhibitors of Wnt pathway are being
actively developed in cancer medicine and it is possible that
these may also find a role in enhancing remyelination by
inhibiting Wnt signaling in CNS precursors and normalizing
the kinetics of myelin regeneration [81, 82].
Currently RXR agonists are being tested for the treatment
of certain cancers, and are also thought to be useful in the
treatment of metabolic disorders [75]. A licensed RXR
agonist Targretin (bexarotene, Eisai Inc., Japan) is already
in clinical use for the treatment of cutaneous T-cell
lymphoma [83]. In EAE, a well-established model of
immune-mediated demyelination that mimics many aspects
of MS, 9cRA has been shown to suppress inflammation. Our
work suggests RXR agonists will be of value as a
regenerative therapy, filling the unoccupied niche of a
treatment for progressive MS [84]. Thus, Targretin and other
RXR agonists could conceivably provide an important
advance in MS therapy, contributing not only to damage
suppression through immunomodulation, but also axon
preservation through enhancement of remyelination.
In summary, we have focused on those pathways that have
been shown to regulate the regenerative process of remyeli-
nation. There are an increasing number of pathways and
mechanisms being identified that could potentially play
similar roles [85–88]. As previously indicated, such research
could impact not only MS, but other myelin disorders, such
as periventricular leukomalacia (PVL), in which a critical
window for repair is inadequately addressed by current
therapies. Therefore, the next few years promise to be an
exciting time for remyelination research with the promise of
developing a much better understanding of the pathobiology
of failed remyelination, as well as development of new
pharmacological treatments by which this important regen-
erative process can be promoted.
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